5 Key Takeaways
-
1
Dry eye disease (DED) affects 5% to 50% of individuals globally, impacting quality of life and daily functions.
-
2
The approval of new therapeutics has expanded treatment options for DED, increasing complexity in prescribing.
-
3
A stepwise approach to DED management is recommended, starting with preservative-free artificial tears and escalating as needed.
-
4
Recent treatments include cyclosporine formulations, intranasal sprays, and options for Demodex blepharitis, enhancing management strategies.
-
5
The evolving landscape of DED treatments emphasizes the need for clinicians to stay informed about new therapies and their indications.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.